Skip to main content

Table 2 Univariate and multivariate analysis

From: Prognostic importance of systemic inflammation and insulin resistance in patients with cancer: a prospective multicenter study

Variables

OS (model 0) a

 

OS (model 1) b

 

OS (model 2) c

 

OS (model 3) d

 

OS (model 4) e

 
 

Crude HR (95%CI)

Crude P

Adjusted HR (95%CI)

Adjusted P

Adjusted HR (95%CI)

Adjusted P

Adjusted HR (95%CI)

Adjusted P

Adjusted HR (95%CI)

Adjusted P

CRP

          

as continues

1.24 (1.20-1.28)

<0.001

1.24 (1.19-1.28)

<0.001

1.17 (1.13-1.21)

<0.001

1.14 (1.09-1.18)

<0.001

1.13 (1.09-1.18)

<0.001

as binary

          

By clinical cut-off

          

CRP≤10

1

 

1

 

1

 

1

 

1

 

CRP>10

2.35 (2.16-2.56)

<0.001

2.29 (2.10-2.50)

<0.001

1.75 (1.60-1.91)

<0.001

1.52 (1.39-1.65)

<0.001

1.51 (1.38-1.65)

<0.001

as quartile

          

Q1(<2.60)

1

 

1

 

1

 

1

 

1

 

Q2(2.60-3.71)

1.30 (1.13-1.49)

<0.001

1.30 (1.13-1.50)

<0.001

1.12 (0.97-1.29)

0.117

1.17 (1.02-1.35)

0.029

1.17 (1.01-1.34)

0.031

Q3 (3.71-15.80)

2.07 (1.82-2.35)

<0.001

2.09 (1.85-2.38)

<0.001

1.66 (1.46-1.88)

<0.001

1.56 (1.37-1.77)

<0.001

1.56 (1.37-1.77)

<0.001

Q4 (>15.80)

3.22 (2.85-3.63)

<0.001

3.13 (2.77-3.54)

<0.001

2.15 (1.90-2.43)

<0.001

1.85 (1.63-2.10)

<0.001

1.84 (1.62-2.09)

<0.001

p for trend

 

<0.001

 

<0.001

 

<0.001

 

<0.001

 

<0.001

LHR

          

as continues

1.10 (1.06-1.15)

<0.001

1.11 (1.07-1.15)

<0.001

1.05 (1.02-1.09)

0.004

1.02 (0.99-1.06)

0.262

1.02 (0.98-1.05)

0.332

as binary

          

LHR≤3.56

1

 

1

 

1

 

1

 

1

 

LHR>3.56

1.52 (1.34-1.72)

<0.001

1.59 (1.40-1.80)

<0.001

1.30 (1.14-1.47)

<0.001

1.21 (1.06-1.38)

0.004

1.20 (1.06-1.37)

0.005

as quartile

          

Q1(<1.81)

1

 

1

 

1

 

1

 

1

 

Q2(1.81-2.33)

0.88 (0.78-0.99)

0.038

0.93 (0.82-1.05)

0.213

0.94 (0.83-1.06)

0.286

0.89 (0.79-1.01)

0.068

0.89 (0.78-1.00)

0.057

Q3 (2.33-2.94)

1.02 (0.90-1.15)

0.773

1.10 (0.97-1.24)

0.135

1.04 (0.92-1.17)

0.57

1.04 (0.92-1.17)

0.568

1.03 (0.91-1.16)

0.626

Q4 (>2.94)

1.24 (1.10-1.39)

<0.001

1.36 (1.21-1.53)

<0.001

1.20 (1.07-1.36)

0.002

1.15 (1.02-1.30)

0.022

1.14 (1.01-1.29)

0.034

p for trend

 

<0.001

 

<0.001

 

0.001

 

0.003

 

0.005

  1. Notes: CRP C-reactive protein, LHR LDL-c/HDL-c ratio, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol, HR hazards ratio, CI confidence interval, BMI body mass index, KPS karnofsky performance status
  2. aModel 0: Unadjusted
  3. bModel 1: Adjusted for BMI
  4. cModel 2: Adjusted for age, sex, BMI and TNM stage
  5. dModel 3: Adjusted for age, sex, tumor stage, BMI, tumor types, KPS, surgery, chemotherapy, radiotherapy, smoking, alcohol, and nutritional intervention
  6. eModel 4: Adjusted for age, sex, tumor stage, BMI, tumor types, KPS, surgery, chemotherapy, radiotherapy, smoking, alcohol, nutritional intervention, diabetes, hypertension, and coronary heart disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us